Recovery research fieldbook Evidence, not treatment advice
Recovery archive

Published recovery field note

Tesamorelin 10mg Research Peptide | GHRH | Palmetto Peptides

Tesamorelin 10mg | Stabilized GHRH analog studied for visceral adipose & GH axis research. COA verified. Explore research data. Research use only.

Context first

Study findings do not automatically establish clinical benefit, safety, dosing, or suitability for an individual.

Tesamorelin 10mg Research Peptide

GHRH Analog · HIV-Associated Lipodystrophy Research · COA Verified

For research and laboratory use only. Not for human consumption. By purchasing, you confirm you are a qualified researcher.

Product Details

For Research Purposes Only. Not approved for human consumption.

Tesamorelin Research Peptide 10mg

Tesamorelin is a synthetic analog of Growth Hormone Releasing Hormone (GHRH) specifically engineered with a trans-3-hexenoic acid group to increase resistance to degradation and improve pharmacokinetics. It has been FDA-approved for reducing excess abdominal fat in HIV-associated lipodystrophy, making it one of the few research peptides with established clinical data in a specific metabolic condition. Tesamorelin serves as an important reference compound for researchers studying GHRH analogs in metabolic and body composition research.

Research Applications

GHRH analog pharmacokinetic research

Visceral adipose tissue and metabolic studies

HIV-associated lipodystrophy research models

GH axis and IGF-1 elevation studies

Body composition and lipodystrophy research

Quality Specifications

Purity: ≥98% (HPLC verified)

Compound: Tesamorelin

Molecular Weight: 5135.9 Da

Form: Lyophilized powder

Origin: Made in the USA

Testing: Third-party tested in a US laboratory

Storage: -20°C, protect from light

COA: Batch-specific, ISO-accredited laboratory

Frequently Asked Questions

Q: How does Tesamorelin differ from other GHRH analogs?A: Tesamorelin has a trans-3-hexenoic acid modification for enhanced stability. It is FDA-approved for HIV-associated lipodystrophy — one of the few peptides with clinical approval for a specific indication.

Q: What is lipodystrophy?A: Abnormal fat distribution — either loss (lipoatrophy) or accumulation (lipohypertrophy). Tesamorelin is approved specifically for HIV-associated abdominal lipohypertrophy.

Q: Why is Tesamorelin significant for research?A: Its FDA-approved status provides extensive clinical safety and efficacy data, making it a valuable reference compound when studying newer GHRH analogs.

Related Research: CJC-1295 No DAC | Sermorelin | Ipamorelin

For laboratory research use only. Not for human consumption. Not evaluated by the FDA.

Connected topics

Follow this recovery question